[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"estrogen-replacement-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:estrogen-replacement-therapy":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,77,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100582654","effects-of-estrogen-on-heart-health-in-women-with-primary-ovarian-insufficiency-100582654",false,"NCT06866119","Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency","Effects of Estrogen Replacement on Cardiometabolic Endpoints in Women With Primary Ovarian Insufficiency","ENCODE","Inclusion criteria (I):\n\n* female sex\n* age 30-40\n* CASE PARTICIPANTS ONLY: clinically documented POI diagnosis within 6 months\n* CASE PARTICIPANTS ONLY: planning to clinically initiate 100mcg transdermal 17beta-estradiol twice weekly and micro-ionized progesterone (either 100mg daily or 200mg cyclically)\n* CONTROL PARTICIPANTS ONLY: regular menstrual cycles every 21-35 days\n\nExclusion criteria (E):\n\n* CASE PARTICIPANTS ONLY: genetic POI etiology\n* CASE PARTICIPANTS ONLY: any prior initiation of ERT\n* systemic estrogen, progesterone or testosterone therapy within the past 6 months (including contraception, except for locally acting intrauterine devices - IUDs)\n* lipid lowering therapy within the past 6 months\n* use of antihypertensive medication within the past 6 months\n* current treatment with prescription, systemic (oral, IV, or IM) steroids or anti-inflammatory\u002Fimmune suppressant medical therapies (excluding topical therapies, UV therapy, ASA-derivative therapies, or NSAIDS) for autoimmune\u002Finflammatory diseases (psoriasis, RA, IBD, lupus), post-transplant care, asthma, or pain syndromes\n* use of oral steroids or prescription oral anti-inflammatory\u002Fimmune suppressant medication for \\>7 days within the past 1 month\n* use of IV or IM steroids or IV or IM anti-inflammatory\u002Fimmune suppressant medication within the past 3 months\n* self-reported history of breast and\u002For estrogen dependent malignancy\n* self-reported history of deep vein thromboembolism, pulmonary embolism or stroke\n* self-reported severe liver disease such as cirrhosis\n* self-reported hypercoagulable disorder\n* uncontrolled hypertension at baseline Visit #1- systolic blood pressure (SBP) ≥180 and\u002For diastolic blood pressure (DBP) ≥110\n* tobacco use within 6 months\n* self-reported history of myocardial infarction, stroke, coronary revascularization or diabetes as a CVD risk equivalent\n* stable or unstable angina\n* self-reported history of heart failure\n* pregnancy or breastfeeding\n* concurrent enrollment in conflicting research study",true,"FEMALE","30 Years","40 Years",{"count":22,"type":23},45,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to study the effects of treating women with Primary Ovarian Insufficiency (POI) with estrogen replacement therapy to bolster the evidence backing cardiometabolic preventive care in women with POI. The main question it aims to answer is:\n\nDoes 6 months of estrogen replacement therapy for women with POI improved markers of heart health?\n\nWomen newly diagnosed with POI (within 6 months) who are planning to start estrogen replacement therapy from their clinical provider will undergo assessment of markers of heart health before and after 6 months of treatment. These markers will also be compared to those obtained from healthy women without POI.",[27,28,29,30,31],"Primary Ovarian Insufficiency","Premature Menopause","Metabolic Complications","Endothelial Function (FMD)","Estrogen Replacement Therapy",[33,34,35,36,37,38],"primary ovarian insufficiency","premature menopause","estrogen replacement therapy","cardiovascular disease prevention","POI","ERT","NOT_YET_RECRUITING","2026-01-05",{"date":42,"type":43},"2026-01-07","ACTUAL",{"date":45,"type":23},"2026-03-01",{"date":47,"type":23},"2026-06",{"name":49,"class":50},"Massachusetts General Hospital","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":18,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":51},"100476415","compare-vaginal-estrogen-and-platelet-rich-plasma-over-women-with-genitourinary-syndrome-of-menopause-100476415","NCT05483634","Compare Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause","Compare the Effectiveness and Side Effects of Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause","Inclusion Criteria:\n\n* Women with menopause\n* Patients with symptoms of genitourinary syndrome of menopause\n\nExclusion Criteria:\n\n* Genitourinary bleeding or infection without definitive diagnosis\n* Coagulopathy\n* Allergy to medication or therapy related with the treatment\n* Chronic disease that might influence outcome\n* Using medication that might influence outcome in 30 days\n* Using hormone or steroid within 8 weeks","45 Years","80 Years",{"count":62,"type":23},40,"The definition of Genitourinary Syndrome of Menopause (GSM) is the decline of estrogens during menopause results in symptoms and clinical signs from both systems. Estrogen and other hormones production decrease after menopause because the ovaries lose their effectiveness, leading to mucosal atrophy, reduced vaginal moisture, dysuria, urgency, recurrent infection, burning, pruritus and dyspareunia.\n\nThe treatment included vaginal estrogen supplement, vaginal hyaluronic acid supplement, vaginal laser, platelet rich plasma, etc. Observational cohort study will be used for study design, and questionnaire, pelvic examination, vaginal pap smear with maturation index (MI), vaginal pH, and other methods will be used for evaluation of the effectiveness and side effects.",[65,66,31,67],"Menopause","Platelet-rich Plasma","Vaginal Atrophy","2025-05-06",{"date":70,"type":43},"2025-05-09",{"date":72,"type":23},"2025-12-01",{"date":74,"type":23},"2027-06-30",{"name":76,"class":50},"Mackay Memorial Hospital",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":18,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":97,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":51},"100557927","phase-4-determining-dose-equivalence-between-oral-and-transdermal-estrogen-treatment-in-women-with-turner-syndrome-100557927","NCT06544473","Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome","Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome - A Randomized Study","Inclusion Criteria:\n\n* Diagnosis of TS regardless of karyotype\n* Age 18-50 years\n* Already receiving estrogen treatment\n\nExclusion Criteria:\n\n* Active systemic chronic diseases\n* Known or suspected breast cancer\n* Known or suspected estradiol-dependent tumors (endometrial cancer or similar)\n* Untreated endometrial hyperplasia\n* Current or previous venous thromboembolism\n* Acute or previous liver disease where liver enzymes are still elevated by a factor 3 or more\n* Known hypersensitivity to the medications used\n* Pregnancy","18 Years","50 Years",{"count":87,"type":23},50,"INTERVENTIONAL",[90],"PHASE4","This 5-week, phase IV randomized crossover trial aims to compare the effects of oral versus transdermal estrogen replacement therapy (ERT) in women with Turner syndrome (TS). The objective is to establish the equipotency between the two estradiol regimens by evaluating various estradiol-dependent surrogate markers. The study involves 50 women with TS, aged 18-50 years, who are randomized to receive either oral or transdermal ERT for 14 days, followed by a crossover to the alternate treatment for another 14 days, with a one-week washout period in between. Blood tests are conducted at baseline, after the first 14 days of treatment, after the washout period, and after the final 14 days of treatment. The investigators anticipate that this study will provide clinicians with a better understanding of ERT in treating women with TS.",[93,94,95,31,96],"Turner Syndrome","Hypogonadism; Ovarian","Hormone Replacement Therapy","Estrogen Deficiency",[98,95,31,99,100],"Turner syndrome","Estrogen treatment","Dose equipotency","RECRUITING","2024-08-22",{"date":104,"type":43},"2024-08-23",{"date":106,"type":43},"2021-11-29",{"date":108,"type":23},"2026-12-31",{"name":110,"class":50},"Aarhus University Hospital",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":17,"sex":18,"minAge":84,"maxAge":85,"enrollmentInfo":118,"targetDuration":4,"studyType":88,"phases":119,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":129,"leadSponsor":130,"locationsCount":51},"100559924","phase-4-long-term-effects-of-oral-versus-transdermal-estrogen-replacement-therapy-in-turner-syndrome-100559924","NCT06570460","Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome","Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome - A Randomized Trial","Inclusion criteria:\n\nFor participants with TS:\n\n* Diagnosis of TS regardless of karyotype\n* Age 18-50 years\n* Already receiving estrogen treatment\n\nFor healthy controls:\n\n* Female\n* Age 18-50 years\n* Previously healthy\n* Not receiving any medication\n* Not using any form of contraceptive pills\n* No mental or psychiatric disorders\n\nExclusion criteria:\n\n* Active systemic chronic diseases\n* Known or suspected breast cancer\n* Known or suspected estradiol-dependent tumors (endometrial cancer or similar)\n* Untreated endometrial hyperplasia\n* Current or previous venous thromboembolism\n* Acute or previous liver disease where liver enzymes are still elevated by a factor 3 or more\n* Known hypersensitivity to the medications used\n* Pregnancy\n* Menopause (for the control group only)",{"count":87,"type":23},[90],"This 14-month, phase IV, randomized controlled crossover trial aims to compare the effects of oral versus transdermal estrogen replacement therapy (ERT) in women with Turner syndrome (TS). The study's objectives are to clarify endocrine, metabolic, cardiovascular, and thromboembolic risk factors in TS after a wash-out period without estrogen (E2) treatment; compare the effects of oral versus transdermal (TD) ERT regimens; and examine the long-term effects of E2 administration via these two routes. The study involves 50 TS women aged 18-50 years and 50 control participants. TS participants are randomized to receive either oral or TD ERT for six months, followed by crossover to the alternate treatment for another six months. Prior to randomization, any existing ERT will be discontinued for a 1-month washout period. A second 1-month washout period will occur between the two 6-month treatment phases. Laboratory analyses and clinical investigations are performed after the first wash-out period, after the first six months of treatment, and after the last six months of treatment. We anticipate that this study may provide a basis for new and improved recommendations for sex hormone replacement therapy in TS.",[93,94,95,31,96],[98,123,124,99,125],"Hormone replacement therapy","Estrogen replacement therapy","Long term side effects",{"date":127,"type":43},"2024-08-26",{"date":106,"type":43},{"date":108,"type":23},{"name":110,"class":50}]